Boehringer Ingelheim

FRANKFURT AM MAIN, Germany — September 17, 2026 Merz Therapeutics announced that it has received European Union and European...

INGELHEIM, Germany — September 17, 2026 Boehringer Ingelheim announced the launch of PED Essentials, a free online learning hub...

Ingelheim, Germany, and Bracknell, United Kingdom, September 1, 2026 Boehringer Ingelheim has launched SCOVELLA® (velagliflozin oral solution) in Great...

Toronto, Ontario, Canada, USA 10, 2026 Creyos has announced initial results from its implementation of digital cognitive testing across...

Johns Creek, Georgia, August, USA 10, 2026 Boehringer Ingelheim Animal Health is highlighting the next generation of veterinary researchers...

WASHINGTON, July 16, 2026 Vanda Pharmaceuticals has announced that the Committee for Orphan Medicinal Products (COMP) at the European...

INGELHEIM, Germany, July 17, 2026 Boehringer Ingelheim has announced that the European Commission (EC) has granted marketing authorization for...

INGELHEIM, Germany, July 16, 2026 Boehringer Ingelheim has initiated a Phase II clinical trial evaluating BI 3034701, an investigational...

INGELHEIM, Germany, July 15, 2026 Boehringer Ingelheim reported strong financial and operational performance for the first half of 2026,...

INGELHEIM, Germany, June 18, 2026 Boehringer Ingelheim has announced new long-term survival modeling analyses from its pivotal Phase III...